Kaken Seiyaku (4521) said first-half net profit attributable to owners of the parent rose 698.1% to ¥8.0 billion, driven by a US$70 million milestone payment from Johnson & Johnson.
For the six months ended Sept. 30, 2026, the company attributed higher sales and profit to increased overseas sales after it received the milestone income under a license agreement with J&J announced on April 22, 2026. Earnings per share were ¥211.29. R&D expenses fell 14.8% to ¥9.94 billion.
| Item | H1 FY3/2027 | H1 FY3/2026 |
|---|---|---|
| Sales | ¥48.96 billion | ¥39.36 billion |
| Operating profit | ¥10.16 billion | ¥180 million |
| Ordinary profit | ¥10.71 billion | ¥584 million |
| Net profit | ¥8.00 billion | ¥1.00 billion |
Kaken Seiyaku kept its full-year forecast unchanged: sales of ¥89.9 billion, up 17.0%, operating profit of ¥7.9 billion and net profit of ¥6.5 billion, up 203.1%. It declared an interim dividend of ¥95 per share and maintained its annual dividend forecast of ¥190.
During the period, the company filed for marketing approval for KP-001, for refractory vascular malformations, and KAR, for head lice. Its European licensee Almirall launched nail fungus treatment Jublia in Germany, the group's first product in the European market.
The board also approved the absorption of wholly owned subsidiary ARTham Therapeutics, a drug research company with capital of ¥100 million. As a simplified and short-form merger, it requires no shareholder approval and involves no allotment of shares or cash. The company said the impact on consolidated results will be minor.
Next steps: Kaken Seiyaku plans to file its semiannual report on Nov. 12, 2026, and begin dividend payments on Nov. 30, 2026. The merger is scheduled to take effect on Dec. 31, 2026.
| I-ne | |
| Tender offer price | ¥2,248 per share |
| Kadoya Seiyu | |
| Tender offer price | ¥2,655 per share |
| TKP Corporation | |
| Effective date | March 1, 2027 (scheduled) |
| M3, Inc. | |
| Tender offer price | ¥1,619 per share |
| Digital Hearts Holdings | |
| Consolidation ratio | 2,975,211 shares into 1 share |
| Shoei Corporation | |
| Shares transferred | 1.8 million shares |
| TOSE Co., Ltd. | |
| Effective date (scheduled) | Jan. 4, 2027 |
| NSK Ltd. | |
| Share transfer ratio (NSK:NTN) | 1:0.353 |
| M&A / TOB | 20 |
| Guidance | 7 |
| Buybacks | 11 |
| Dividends | 4 |
| Capital | 12 |
| Earnings | 16 |
| People | 3 |
Summaries of public disclosures by Japanese listed companies. Not investment advice; accuracy not guaranteed. Figures and dates in the TDnet originals prevail.
本站內容為日本上市公司公開開示之摘要整理,非投資建議,亦不保證正確。數字與日程以 TDnet 原文為準。
本サイトは日本の上場企業の適時開示を要約したものであり、投資助言ではありません。正確性は保証しません。数値・日程は TDnet の原文が優先します。